Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$71.05
-3.6%
$64.50
$23.65
$77.00
$6.50B0.311.20 million shs1.41 million shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$39.79
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$58.02
$57.90
$5.67
$58.02
$1.61B0.494.25 million shsN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$102.88
+4.6%
$68.71
$23.30
$104.23
$6.13B2.232.15 million shs1.99 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-3.63%+8.09%+14.06%+6.38%+173.27%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%+1.86%+1.61%+208.22%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
0.00%0.00%0.00%0.00%+625.25%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+4.60%+21.04%+53.85%+107.67%+179.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$71.05
-3.6%
$64.50
$23.65
$77.00
$6.50B0.311.20 million shs1.41 million shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$39.79
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$58.02
$57.90
$5.67
$58.02
$1.61B0.494.25 million shsN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$102.88
+4.6%
$68.71
$23.30
$104.23
$6.13B2.232.15 million shs1.99 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-3.63%+8.09%+14.06%+6.38%+173.27%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%+1.86%+1.61%+208.22%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
0.00%0.00%0.00%0.00%+625.25%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+4.60%+21.04%+53.85%+107.67%+179.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$81.7315.03% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.21
Hold$41.332.06% Upside
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.15
Hold$48.44-16.50% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.80
Moderate Buy$79.30-22.92% Downside

Current Analyst Ratings Breakdown

Latest RAPT, CGON, CNTA, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
5/19/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Initiated CoveragePeer Perform
(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,551.14N/AN/A$9.33 per share7.62
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/A$3.92 per shareN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/A$11.51 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M17.01N/AN/A$7.84 per share13.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$11.06N/AN/AN/AN/A-61.81%-54.73%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest RAPT, CGON, CNTA, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million
5/5/2026Q1 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.52-$0.14-$0.52N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
31.30
31.25
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.23
9.53
9.53
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
12.04
12.04
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4.09%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.36%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.20 million83.97 millionOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200154.73 million148.40 millionOptionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8027.71 million27.06 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Dennis Cho Sells 14,205 Shares of Twist Bioscience (NASDAQ:TWST) Stock
TWST Share News Today

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$71.05 -2.68 (-3.63%)
Closing price 06/30/2026 04:00 PM Eastern
Extended Trading
$70.00 -1.05 (-1.48%)
As of 06/30/2026 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$40.50 0.00 (0.00%)
As of 06/25/2026

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$102.88 +4.52 (+4.60%)
Closing price 06/30/2026 04:00 PM Eastern
Extended Trading
$102.50 -0.38 (-0.37%)
As of 06/30/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.